Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
China Pharmacist ; (12): 1260-1261,1298, 2017.
Artigo em Chinês | WPRIM | ID: wpr-617591

RESUMO

Objective: To investigate the effect of alendronate on serum total alkaline phosphatase (AKP) and bone specific alkaline phosphatase (BAP) in the elderly female patients with postmenopausal osteoporosis and explore their correlations.Methods: A retrospective study was performed.Totally 286 elderly female patients with postmenopausal osteoporosis were divided into two groups(according to AKP levels before the treatment of alendronate): the normal AKP group (n=245) and the elevated AKP group (n=41).Raised AKP of all the patients in the elevated AKP group was not associated with hepatobiliary problems.The changes of AKP and BAP levels were analyzed after the treatment of alendronate.The correlations between BAP and AKP levels before and after the treatment of alendronate were analyzed, as well as between the changes in AKP (ΔAKP) and BAP (ΔBAP) levels.Results: AKP and BAP tended to be higher in elderly patients.BAP levels in the normal AKP group were higher than those in the elevated AKP group (P<0.05).BAP was signicantly correlated with AKP both before and after the treatment (P<0.05), as well as the correlation between ΔAKP and ΔBAP (P<0.05).Conclusion: AKP and BAP both tend to increase with age.In elderly female patients with postmenopausal osteoporosis and elevated AKP associated with non-hepatobiliary problems, alendronate treatment can lower AKP levels, and the decrease is strongly correlated with the decrease in BAP.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA